|
gptkbp:instanceOf
|
antiviral drug
|
|
gptkbp:administeredBy
|
dry powder inhaler
|
|
gptkbp:approvalYear
|
1999
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J05AH01
|
|
gptkbp:bioavailability
|
2% (oral inhalation)
|
|
gptkbp:brand
|
gptkb:Relenza
|
|
gptkbp:CASNumber
|
139110-80-8
|
|
gptkbp:contraindication
|
asthma
chronic obstructive pulmonary disease
|
|
gptkbp:developedBy
|
GlaxoSmithKline
|
|
gptkbp:discoveredBy
|
gptkb:Mark_von_Itzstein
|
|
gptkbp:drugClass
|
neuraminidase inhibitor
|
|
gptkbp:eliminationHalfLife
|
2.5-5.1 hours
|
|
gptkbp:firstSynthesized
|
1990s
|
|
gptkbp:hasMolecularFormula
|
C12H20N4O7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zanamivir
|
|
gptkbp:KEGGID
|
D08645
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits influenza virus neuraminidase
|
|
gptkbp:notRecommendedFor
|
children under 7 years
patients with respiratory disease
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL123
54813
60855
DB00520
|
|
gptkbp:routeOfAdministration
|
inhalation
|
|
gptkbp:sideEffect
|
headache
cough
bronchospasm
|
|
gptkbp:UNII
|
R7T0EZ6389
|
|
gptkbp:usedFor
|
gptkb:influenza_A
gptkb:influenza_B
|
|
gptkbp:bfsParent
|
gptkb:Influenza_Virus
|
|
gptkbp:bfsLayer
|
6
|